$GRCE

2022 Q1 Form 10-K Financial Statement

#000095017022011842 Filed on June 21, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2022 2021 Q1
Revenue $0.00 $0.00 $115.0K
YoY Change -100.0% -100.0%
Cost Of Revenue $0.00 $0.00 $40.00K
YoY Change -100.0% -100.0%
Gross Profit $0.00 $0.00 $75.00K
YoY Change -100.0% -100.0%
Gross Profit Margin 65.22%
Selling, General & Admin $2.077M $9.781M $1.509M
YoY Change 37.64% 46.8% -82.17%
% of Gross Profit 2012.0%
Research & Development $848.0K $5.559M $393.0K
YoY Change 115.78% 33.21% -97.54%
% of Gross Profit 524.0%
Depreciation & Amortization $0.00 $0.00 $1.000K
YoY Change -100.0% -100.0% -99.76%
% of Gross Profit 1.33%
Operating Expenses $4.403M $15.34M $1.962M
YoY Change 124.41% 41.57% -91.97%
Operating Profit -$4.403M -$15.59M -$1.887M
YoY Change 133.33% -5.06%
Interest Expense -$296.0K $4.975M -$3.346M
YoY Change -91.15% -266.11% 278.51%
% of Operating Profit
Other Income/Expense, Net $147.0K $5.122M $0.00
YoY Change -257.16% -100.0%
Pretax Income -$4.552M -$10.47M -$5.646M
YoY Change -19.38% -46.81% -77.87%
Income Tax -$648.0K -$648.0K
% Of Pretax Income
Net Earnings -$3.904M -$9.819M -$5.646M
YoY Change -30.85% -50.1% -77.87%
Net Earnings / Revenue -4909.57%
Basic Earnings Per Share -$0.27
Diluted Earnings Per Share -$106.0K -$266.5K -$239.8K
COMMON SHARES
Basic Shares Outstanding 44.29M 36.84M 179.5M
Diluted Shares Outstanding 36.84M

Balance Sheet

Concept 2022 Q1 2022 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $43.66M $43.66M $60.73M
YoY Change -28.11% -28.11% 326.48%
Cash & Equivalents $30.34M $30.34M $50.94M
Short-Term Investments $13.32M $13.32M $9.789M
Other Short-Term Assets $1.322M $1.322M $1.111M
YoY Change 18.99% 18.99% 469.74%
Inventory
Prepaid Expenses $720.0K $343.0K
Receivables $548.0K $530.0K
Other Receivables $18.00K
Total Short-Term Assets $45.28M $45.53M $62.37M
YoY Change -27.4% -27.0% 237.84%
LONG-TERM ASSETS
Property, Plant & Equipment $20.89M $315.0K
YoY Change 266.28%
Goodwill $12.96M
YoY Change
Intangibles $69.81M $0.00
YoY Change -100.0%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $83.34M $83.09M $86.00K
YoY Change 96805.81% 96515.12% -98.04%
TOTAL ASSETS
Total Short-Term Assets $45.28M $45.53M $62.37M
Total Long-Term Assets $83.34M $83.09M $86.00K
Total Assets $128.6M $128.6M $62.46M
YoY Change 105.93% 105.93% 173.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.156M $1.678M $115.0K
YoY Change 2644.35% 1359.13% -93.29%
Accrued Expenses $296.0K $1.286M $607.0K
YoY Change -51.24% 50.06% -85.71%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $3.260M $3.260M $1.579M
YoY Change 106.46% 106.46% -78.65%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $201.0K $201.0K $5.219M
YoY Change -96.15% -96.15% 111.81%
Total Long-Term Liabilities $201.0K $201.0K $5.219M
YoY Change -96.15% -96.15% 111.81%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.260M $3.260M $1.579M
Total Long-Term Liabilities $201.0K $201.0K $5.219M
Total Liabilities $20.35M $20.35M $6.798M
YoY Change 199.35% 199.35% -31.05%
SHAREHOLDERS EQUITY
Retained Earnings -$155.8M -$146.0M
YoY Change 6.72% 15.58%
Common Stock $258.0M $197.2M
YoY Change 30.83% 43.49%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $108.3M $108.3M $55.66M
YoY Change
Total Liabilities & Shareholders Equity $128.6M $128.6M $62.46M
YoY Change 105.93% 105.93% 173.3%

Cashflow Statement

Concept 2022 Q1 2022 2021 Q1
OPERATING ACTIVITIES
Net Income -$3.904M -$9.819M -$5.646M
YoY Change -30.85% -50.1% -77.87%
Depreciation, Depletion And Amortization $0.00 $0.00 $1.000K
YoY Change -100.0% -100.0% -99.76%
Cash From Operating Activities -$3.145M -$17.23M -$1.760M
YoY Change 78.69% 20.36% -92.33%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $11.00K -$3.522M -$8.417M
YoY Change -100.13% -64.02% 2174.86%
Cash From Investing Activities $11.00K -$3.522M -$8.417M
YoY Change -100.13% -64.27% -203.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 34.68M
YoY Change -100.0% -100.0% 163.19%
NET CHANGE
Cash From Operating Activities -3.145M -17.23M -1.760M
Cash From Investing Activities 11.00K -3.522M -8.417M
Cash From Financing Activities 0.000 0.000 34.68M
Net Change In Cash -3.134M -20.60M 24.50M
YoY Change -112.79% -156.14% -1603.13%
FREE CASH FLOW
Cash From Operating Activities -$3.145M -$17.23M -$1.760M
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow -$3.145M -$17.23M -$1.760M
YoY Change 78.69% 20.94% -92.43%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--03-31
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001444192
CY2022 us-gaap Write Off Of Deferred Debt Issuance Cost
WriteOffOfDeferredDebtIssuanceCost
CY2021 us-gaap Other Income
OtherIncome
CY2021Q1 acst Licenses
Licenses
CY2021Q1 us-gaap Goodwill
Goodwill
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2022Q1 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
CY2022 dei No Trading Symbol Flag
NoTradingSymbolFlag
true
CY2021Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-35776
CY2022 dei Entity Registrant Name
EntityRegistrantName
ACASTI PHARMA INC.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
Z4
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1359336
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
3009 boul. de la Concorde East, Suite 102
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Laval
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
QC
CY2022 dei Entity Address Country
EntityAddressCountry
CA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
H7E 2B5
CY2022 dei City Area Code
CityAreaCode
450
CY2022 dei Local Phone Number
LocalPhoneNumber
687-2262
CY2022 dei Security12b Title
Security12bTitle
Common Shares, no par value per share
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
44439758
CY2022 dei Auditor Firm
AuditorFirmId
85
CY2022 dei Auditor Name
AuditorName
KPMG LLP
CY2022 dei Auditor Location
AuditorLocation
Montréal, QC, Canada
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30339000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50942000
CY2022Q1 us-gaap Short Term Investments
ShortTermInvestments
13322000
CY2021Q1 us-gaap Short Term Investments
ShortTermInvestments
9789000
CY2022Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
548000
CY2021Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
530000
CY2022Q1 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
602000
CY2021Q1 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
768000
CY2022Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
720000
CY2021Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
343000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
45531000
CY2021Q1 us-gaap Assets Current
AssetsCurrent
62372000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
315000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
86000
CY2022Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
69810000
CY2022Q1 us-gaap Goodwill
Goodwill
12964000
CY2022Q1 us-gaap Assets
Assets
128620000
CY2021Q1 us-gaap Assets
Assets
62458000
CY2022Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3156000
CY2021Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1493000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
104000
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
86000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
3260000
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1579000
CY2022Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
10000
CY2021Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
5219000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
191000
CY2022Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
16889000
CY2022Q1 us-gaap Liabilities
Liabilities
20350000
CY2021Q1 us-gaap Liabilities
Liabilities
6798000
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
257990000
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
197194000
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
12154000
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
10817000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6037000
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6333000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-155837000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-146018000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
108270000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
55660000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
128620000
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
62458000
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
196000
CY2022 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0
CY2021 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
76000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5559000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4173000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9263000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5521000
CY2022 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
518000
CY2021 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1142000
CY2022 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2021 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
3706000
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
1584000
CY2022 acst Impairment Of Other Assets And Prepaids
ImpairmentOfOtherAssetsAndPrepaids
249000
CY2021 acst Impairment Of Other Assets And Prepaids
ImpairmentOfOtherAssetsAndPrepaids
413000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-15589000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-16419000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5122000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3259000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10467000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19678000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-648000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-9819000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-19678000
CY2022 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.33
CY2022 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36841762
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14828232
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
55660000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-9819000
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
296000
CY2022 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1337000
CY2022 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
60796000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
108270000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
12994000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-19678000
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1554000
CY2021 acst Stock Issued During Period Value Warrant Exercises
StockIssuedDuringPeriodValueWarrantExercises
183000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
59336000
CY2021 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1271000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
55660000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-9819000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-19678000
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
781000
CY2022 us-gaap Depreciation
Depreciation
0
CY2021 us-gaap Depreciation
Depreciation
143000
CY2022 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2021 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
3706000
CY2022 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2021 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
1584000
CY2022 acst Impairment Of Other Assets And Prepaids
ImpairmentOfOtherAssetsAndPrepaids
249000
CY2021 acst Impairment Of Other Assets And Prepaids
ImpairmentOfOtherAssetsAndPrepaids
413000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
1337000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
1174000
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5197000
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2426000
CY2022 acst Write Off Of Deferred Financing Costs Of At The Market Program
WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram
0
CY2021 acst Write Off Of Deferred Financing Costs Of At The Market Program
WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram
264000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-648000
CY2022 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
370000
CY2021 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-814000
CY2022 acst Increase Decrease In Working Capital
IncreaseDecreaseInWorkingCapital
2786000
CY2021 acst Increase Decrease In Working Capital
IncreaseDecreaseInWorkingCapital
5946000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17234000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14319000
CY2022 us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
0
CY2021 us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
69000
CY2022 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
34929000
CY2021 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
9810000
CY2022 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
31407000
CY2021 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
21000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3522000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9858000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
59332000
CY2022 acst Payments For Proceeds From Financing Costs
PaymentsForProceedsFromFinancingCosts
0
CY2021 acst Payments For Proceeds From Financing Costs
PaymentsForProceedsFromFinancingCosts
143000
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
183000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
118000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
59490000
CY2022 acst Effect Of Translation Effect On Cash And Cash Equivalents
EffectOfTranslationEffectOnCashAndCashEquivalents
26000
CY2021 acst Effect Of Translation Effect On Cash And Cash Equivalents
EffectOfTranslationEffectOnCashAndCashEquivalents
6329000
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
127000
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-4940000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-20603000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
36702000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
50942000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14240000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
30339000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
50942000
CY2022Q1 us-gaap Cash
Cash
30339000
CY2021Q1 us-gaap Cash
Cash
38406000
CY2022Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2021Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
12536000
CY2022 us-gaap Nature Of Operations
NatureOfOperations
<span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Nature of Operations</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Acasti Pharma Inc. (“Acasti” or the “Corporation”) is incorporated under the Business Corporations Act (Québec) (formerly Part 1A of the Companies Act (Québec)). The Corporation is domiciled in Canada and its registered office is located at 3009 boul. de la Concorde East, Suite 102, Laval, Québec, Canada H7E 2B5.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"> </span> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">In January 2020 and August 2020, the Corporation released Phase 3 TRILOGY clinical study results for the Corporation’s lead drug candidate, CaPre. The TRILOGY studies did not meet the primary endpoint which resulted in the Corporation’s Board of Directors deciding not to proceed with a filing of an NDA with the FDA. With the completion of the TRILOGY studies beginning in the second half of fiscal 2021, marketing and research and development activities and expenses were reduced while management undertook a strategic review, and some CaPre related equipment and other assets were and continue to be classified as held for sale as they are expected to be sold.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"> </span> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">In August 2021, the Corporation completed the acquisition via a share-for-share merger of Grace Therapeutics, Inc. (“Grace”) a privately held emerging biopharmaceutical company focused on developing innovative drug delivery technologies for the treatment of rare and orphan diseases. The post-merger Corporation is focused on building a late-stage specialty pharmaceutical company specializing in rare and orphan diseases and focused on developing and commercializing products that improve the standard of care using novel drug delivery technologies. The Corporation seeks to apply new proprietary formulations to existing pharmaceutical compounds to achieve enhanced efficacy, faster onset of action, reduced side effects, more convenient delivery and increased patient compliance; all of which could result in improved patient outcomes. The active pharmaceutical ingredients chosen by the Corporation for further development may be already approved in the target indication or could be repurposed for use in new indications.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"> </span> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">The Corporation has incurred operating losses and negative cash flows from operations in each year since its inception. The Corporation expects to incur significant expenses and continued operating losses for the foreseeable future. The Corporation expects its expenses will increase substantially in connection with its ongoing activities, particularly as it advances clinical development for the first three drug candidates in the Corporation’s pipeline; continues to engage contract manufacturing organizations (“CMOs”) to manufacture its clinical study materials and to ultimately develop large-scale manufacturing capabilities in preparation for commercial launch; seeks regulatory approval for its product candidates; and adds personnel to support its product development and future product launch and commercialization.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"> </span> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">The Corporation does not expect to generate revenue from product sales unless and until it successfully completes drug development and obtains regulatory approval, which the Corporation expects will take several years and is subject to significant uncertainty. To date, the Corporation has financed its operations primarily through public offerings and private placements of its common shares, warrants and convertible debt and the proceeds from research tax credits. Until such time that the Corporation can generate significant revenue from product sales if ever, it will require additional financing, which is expected to be sourced from a combination of public or private equity or debt financings or other non-dilutive sources, which may include fees, milestone payments and royalties from collaborations with third parties. Arrangements with collaborators or others may require the Corporation to relinquish certain rights related to its technologies or drug product candidates. Adequate additional financing may not be available to the Corporation on acceptable terms, or at all. The Corporation’s inability to raise capital as and when needed would have a negative impact on its financial condition and its ability to pursue its business strategy.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"> </span> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">The Corporation remains subject to risks similar to other development stage companies in the biopharmaceutical industry, including compliance with government regulations, protection of proprietary technology, dependence on third party contractors and consultants and potential product liability, among others.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"> </span> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reverse stock split</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"> </span> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">On August 26, 2021, the shareholders of the Corporation approved a resolution to undertake a reverse split of the common stock within a range of 1-6 to 1-8 with such specific ratio to be approved by the Acasti Board. All references in these financial statements to number of common shares, warrants and options, price per share and weighted average number of shares outstanding prior to the reverse split have been adjusted to reflect the approved reverse stock split of 1-</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">, which was made effective on August 31, 2021, on a retrospective basis as of the earliest period presented.</span></p>
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, income, and expenses. Actual results may differ from these estimates.</span></p><p style="text-indent:-0.013%;padding-left:0.013%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Estimates are based on management’s best knowledge of current events and actions that management may undertake in the future. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Estimates and assumptions include the measurement of derivative warrant liabilities (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">note 11</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">) stock-based compensation (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">note 15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">)) assets held for sale (notes 8) the supply contract (note 20(a)) and acquisition of Grace and valuation of intangibles (note 4). Estimates and assumptions are also involved in measuring the accrual of services rendered with respect to research and developments expenditures at each reporting date, are determining which research and development expenses qualify for research and development tax credits and in what amounts. The Corporation recognizes the tax credits once it has reasonable assurance that they will be realized. Recorded tax credits are subject to review and approval by tax authorities and, therefore, could be different from the amounts recorded.</span></p>
CY2021 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
3706000
CY2021 us-gaap Asset Impairment Charges
AssetImpairmentCharges
1584000
CY2021Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
792000
CY2022 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2021Q1 us-gaap Disposal Group Including Discontinued Operation Property Plant And Equipment
DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
381000
CY2021 us-gaap Depreciation
Depreciation
143000
CY2022Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
32390
CY2022Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
161000
CY2021Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
247881
CY2022 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-13734000
CY2022Q1 acst Sales Tax Receivables Current
SalesTaxReceivablesCurrent
184000
CY2021Q1 acst Sales Tax Receivables Current
SalesTaxReceivablesCurrent
160000
CY2022Q1 acst Grants And Investment Tax Credit Receivable
GrantsAndInvestmentTaxCreditReceivable
353000
CY2021Q1 acst Grants And Investment Tax Credit Receivable
GrantsAndInvestmentTaxCreditReceivable
339000
CY2022Q1 us-gaap Interest Receivable Current
InterestReceivableCurrent
11000
CY2021Q1 us-gaap Interest Receivable Current
InterestReceivableCurrent
13000
CY2021Q1 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
18000
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
548000
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
530000
CY2022Q1 us-gaap Marketable Securities
MarketableSecurities
13322000
CY2021Q1 us-gaap Marketable Securities
MarketableSecurities
9789000
CY2021 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
3706000
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
781000
CY2022 acst Impairment Of Other Assets And Prepaids
ImpairmentOfOtherAssetsAndPrepaids
249000
CY2021 acst Impairment Of Other Assets And Prepaids
ImpairmentOfOtherAssetsAndPrepaids
413000
CY2022Q1 acst Disposal Group Including Discontinued Operation Property Plant And Equipment Cost
DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCost
1875000
CY2022Q1 acst Disposal Group Including Discontinued Operation Property Plant And Equipment Accumulated Depreciation
DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentAccumulatedDepreciation
-1468000
CY2022Q1 us-gaap Disposal Group Including Discontinued Operation Property Plant And Equipment
DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
407000
CY2021Q1 acst Disposal Group Including Discontinued Operation Property Plant And Equipment Cost
DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCost
3459000
CY2021Q1 acst Disposal Group Including Discontinued Operation Property Plant And Equipment Accumulated Depreciation
DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentAccumulatedDepreciation
1494000
CY2021 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
1584000
CY2022Q1 acst Investment Tax Credit Receivable
InvestmentTaxCreditReceivable
353000
CY2021Q1 acst Investment Tax Credit Receivable
InvestmentTaxCreditReceivable
339000
CY2022 acst Proceeds From Nrcirap
ProceedsFromNRCIRAP
0
CY2021 acst Proceeds From Nrcirap
ProceedsFromNRCIRAP
79000
CY2020Q4 acst Award In Nondilutive And Nonrepayable Funding From Nrcirap
AwardInNondilutiveAndNonrepayableFundingFromNRCIRAP
750000
CY2022Q1 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1678000
CY2021Q1 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
115000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
296000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
607000
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1182000
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
771000
CY2022Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3156000
CY2021Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1493000
CY2019Q1 acst Atthemarket Sales Agreement Common Stock Maximum Amount
AtthemarketSalesAgreementCommonStockMaximumAmount
30000000
CY2019Q1 acst Atthemarket Sales Agreement Term
AtthemarketSalesAgreementTerm
P3Y
CY2020Q2 acst Atthemarket Sales Agreement Common Stock Maximum Amount
AtthemarketSalesAgreementCommonStockMaximumAmount
75000000
CY2020Q2 acst Atthemarket Sales Agreement Underwriter Fees Percentage Of Sales
AtthemarketSalesAgreementUnderwriterFeesPercentageOfSales
0.030
CY2021Q4 acst Atthemarket Sales Agreement Common Stock Maximum Amount
AtthemarketSalesAgreementCommonStockMaximumAmount
75000000
CY2021 acst Write Off Of Deferred Financing Costs Of At The Market Program
WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram
264000
CY2022 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-299000
CY2021 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-676000
CY2021 us-gaap Write Off Of Deferred Debt Issuance Cost
WriteOffOfDeferredDebtIssuanceCost
264000
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
77000
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
107000
CY2022 us-gaap Other Income
OtherIncome
147000
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5197000
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2426000
CY2022 acst Transaction Costs Related To Derivative Warrant Liability
TransactionCostsRelatedToDerivativeWarrantLiability
-5122000
CY2021 acst Transaction Costs Related To Derivative Warrant Liability
TransactionCostsRelatedToDerivativeWarrantLiability
3259000
CY2022 acst Unrecognized Compensation Cost Related To Non Vested Share Options
UnrecognizedCompensationCostRelatedToNonVestedShareOptions
1794000
CY2021 acst Unrecognized Compensation Cost Related To Non Vested Share Options
UnrecognizedCompensationCostRelatedToNonVestedShareOptions
476000
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
283637
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
5.97
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2115400
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.75
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
369672
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
4.15
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
29895
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
1.93
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
1999470
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
1.91
CY2022 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P8Y7M13D
CY2022Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
2989381
CY2022Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
989911
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-648000
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-648000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10467000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19678000
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2650
CY2022 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-18000
CY2021 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
58000
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-380000
CY2021 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
672000
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2388000
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
6701000
CY2022 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
0
CY2021 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
25000
CY2022 acst Increase Decrease In Working Capital
IncreaseDecreaseInWorkingCapital
2786000
CY2021 acst Increase Decrease In Working Capital
IncreaseDecreaseInWorkingCapital
5946000
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2650
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-2774000
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-5215000
CY2022 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-77000
CY2021 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
0
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
354000
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
311000
CY2022 acst Income Tax Reconciliation Nondeductible Change In Fair Value
IncomeTaxReconciliationNondeductibleChangeInFairValue
-1377000
CY2021 acst Income Tax Reconciliation Nondeductible Change In Fair Value
IncomeTaxReconciliationNondeductibleChangeInFairValue
643000
CY2022 acst Income Tax Reconciliation Nondeductible Expense Transaction Costs
IncomeTaxReconciliationNondeductibleExpenseTransactionCosts
697000
CY2021 acst Income Tax Reconciliation Nondeductible Expense Transaction Costs
IncomeTaxReconciliationNondeductibleExpenseTransactionCosts
0
CY2022 acst Non Refundable Federal Itc
NonRefundableFederalItc
349000
CY2021 acst Non Refundable Federal Itc
NonRefundableFederalItc
0
CY2022 acst Income Tax Reconciliation Unrecognized Temporary Differences
IncomeTaxReconciliationUnrecognizedTemporaryDifferences
2864000
CY2021 acst Income Tax Reconciliation Unrecognized Temporary Differences
IncomeTaxReconciliationUnrecognizedTemporaryDifferences
4271000
CY2022 acst Effective Income Tax Rate Reconciliation Foreign Exchange Amount
EffectiveIncomeTaxRateReconciliationForeignExchangeAmount
12000
CY2021 acst Effective Income Tax Rate Reconciliation Foreign Exchange Amount
EffectiveIncomeTaxRateReconciliationForeignExchangeAmount
-10000
CY2022 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
2000
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-648000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q1 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
35683000
CY2021Q1 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
28753000
CY2022Q1 acst Deferred Tax Assets Research And Development Expenses
DeferredTaxAssetsResearchAndDevelopmentExpenses
5828000
CY2021Q1 acst Deferred Tax Assets Research And Development Expenses
DeferredTaxAssetsResearchAndDevelopmentExpenses
5424000
CY2022Q1 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
688000
CY2021Q1 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
933000
CY2022Q1 acst Deferred Tax Assets Financing Expenses
DeferredTaxAssetsFinancingExpenses
674000
CY2021Q1 acst Deferred Tax Assets Financing Expenses
DeferredTaxAssetsFinancingExpenses
1167000
CY2022Q1 acst Licenses
Licenses
118000
CY2022Q1 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
3331000
CY2021Q1 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
2968000
CY2022Q1 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
80000
CY2021Q1 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
86000
CY2022Q1 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
46402000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20890000
CY2022Q1 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
20890000
CY2022Q1 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
42401000
CY2021Q1 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
39331000
CY2022Q1 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
16889000

Files In Submission

Name View Source Status
0000950170-22-011842-index-headers.html Edgar Link pending
0000950170-22-011842-index.html Edgar Link pending
0000950170-22-011842.txt Edgar Link pending
0000950170-22-011842-xbrl.zip Edgar Link pending
acst-20220331.htm Edgar Link pending
acst-20220331.xsd Edgar Link pending
acst-ex10_3.htm Edgar Link pending
acst-ex10_6.htm Edgar Link pending
acst-ex23_1.htm Edgar Link pending
acst-20220331_def.xml Edgar Link unprocessable
acst-20220331_cal.xml Edgar Link unprocessable
acst-20220331_pre.xml Edgar Link unprocessable
acst-20220331_lab.xml Edgar Link unprocessable
acst-20220331_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
acst-ex31_1.htm Edgar Link pending
acst-ex31_2.htm Edgar Link pending
acst-ex32_1.htm Edgar Link pending
acst-ex32_2.htm Edgar Link pending
acst-ex4_6.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img179493417_0.jpg Edgar Link pending
img179493417_1.jpg Edgar Link pending
img179493417_10.jpg Edgar Link pending
img179493417_11.jpg Edgar Link pending
img179493417_12.jpg Edgar Link pending
img179493417_13.jpg Edgar Link pending
img179493417_14.jpg Edgar Link pending
img179493417_15.jpg Edgar Link pending
img179493417_2.jpg Edgar Link pending
img179493417_3.jpg Edgar Link pending
img179493417_4.jpg Edgar Link pending
img179493417_5.jpg Edgar Link pending
img179493417_6.jpg Edgar Link pending
img179493417_7.jpg Edgar Link pending
img179493417_8.jpg Edgar Link pending
img179493417_9.jpg Edgar Link pending
img205659619_0.jpg Edgar Link pending
img205659619_1.jpg Edgar Link pending
img99923142_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending